Literature DB >> 15733743

Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.

Daniel Duran-Sandoval1, Bertrand Cariou, Jean-Charles Fruchart, Bart Staels.   

Abstract

Dyslipidemia and gallbladder diseases are two current anomalies observed in patients suffering from the metabolic syndrome and type 2 diabetes. The bile acid-activated nuclear receptor farnesoid X receptor (FXR) controls bile acid as well as lipid metabolism. Recent observations indicate a role for FXR also in carbohydrate metabolism. Hepatic FXR expression is altered in diabetic animal models in vivo and regulated by hormones and nutrients in vitro. At the molecular level, FXR activation modifies the transcriptional activity of different transcription factors controlling gluconeogenesis and lipogenesis, thus affecting in concert bile acid, lipid and carbohydrate metabolism. The present review focuses on recent advances in our understanding of the modulation of carbohydrate metabolism by FXR. These observations raise the intriguing possibility for a modulatory role of this receptor also in the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15733743     DOI: 10.1016/j.biochi.2004.11.018

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  9 in total

Review 1.  Interaction of gut microbiota with bile acid metabolism and its influence on disease states.

Authors:  Alexander Khoruts; Michael J Sadowsky; Christopher Staley; Alexa R Weingarden
Journal:  Appl Microbiol Biotechnol       Date:  2016-11-25       Impact factor: 4.813

Review 2.  Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

Authors:  Pengxiang Huang; Vikas Chandra; Fraydoon Rastinejad
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 3.  Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease.

Authors:  Brent A Neuschwander-Tetri
Journal:  Curr Gastroenterol Rep       Date:  2012-02

4.  Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.

Authors:  Tianwei Zhang; Shanshan Feng; Jiahuan Li; Zhitao Wu; Qiangqiang Deng; Wei Yang; Jing Li; Guoyu Pan
Journal:  Arch Toxicol       Date:  2022-03-10       Impact factor: 6.168

5.  LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice.

Authors:  Thierry Touvier; Françoise Conte-Auriol; Olivier Briand; Céline Cudejko; Réjane Paumelle; Sandrine Caron; Eric Baugé; Yves Rouillé; Jean-Pierre Salles; Bart Staels; Bernard Bailleul
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

Review 6.  Bile acid sequestrants and the treatment of type 2 diabetes mellitus.

Authors:  Bart Staels; Folkert Kuipers
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults.

Authors:  Bertrand Cariou; Maud Chetiveaux; Yassine Zaïr; Etienne Pouteau; Emmanuel Disse; Béatrice Guyomarc'h-Delasalle; Martine Laville; Michel Krempf
Journal:  Nutr Metab (Lond)       Date:  2011-07-07       Impact factor: 4.169

8.  Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate.

Authors:  Maxi Meissner; Hilde Herrema; Theo H van Dijk; Albert Gerding; Rick Havinga; Theo Boer; Michael Müller; Dirk-Jan Reijngoud; Albert K Groen; Folkert Kuipers
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

9.  The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice.

Authors:  Nicole Jw de Wit; Hanneke Bosch-Vermeulen; Philip J de Groot; Guido Jej Hooiveld; Mechteld M Grootte Bromhaar; Jenny Jansen; Michael Müller; Roelof van der Meer
Journal:  BMC Med Genomics       Date:  2008-05-06       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.